Autopsy report · NCT03516084
A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Cause of deathSlow enrollment
“As the treatment model of extensive-stage small cell lung cancer changed rapidly and the enrollment speed significantly lower than expected, ZaiLab decided to terminate this study”
Life of this trial
- Registered 4 months before it started.
- Ran for about 1 year 7 months before it stopped.
- 185 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- ZL-2306(nirapairb); Placebo
- Participants
- 185
- Sites
- 33
- Countries
- China
Trials that died the same way
- Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
“The study was terminated because of slow enrollment. The decision to terminate the trial was not based on any safety or efficacy concerns.” - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
“The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.” - Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting
“The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated for reasons of either safety or efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.